# Charles River Laboratories (CRL) Stock Analysis: Healthcare Innovator with a 5.36% Upside

- Link: https://www.directorstalkinterviews.com/charles-river-laboratories-crl-stock-analysis-healthcare-innovator-with-a-5-36-upside/4121214405
- Published: 2025-09-01T10:29:36+01:00
- Author: Madison Wilson

Charles River Laboratories International, Inc. (NYSE: CRL), a prominent name in 
the healthcare sector’s diagnostics and research industry, continues to capture 
investor attention. With a market cap of $8.04 billion, this Massachusetts-based
company is a key player in drug discovery and safety testing services, extending
its reach across the United States, Europe, Canada, the Asia Pacific, and beyond.

Currently trading at $163.31, CRL’s stock has shown resilience with a 52-week range
between $99.75 and $220.69. The stock’s recent price change is negligible, remaining
flat at 0.09 (0.00%). Despite this stability, analysts see potential in CRL, with
a target price range from $142.00 to $200.00, placing the average target at $172.07.
This suggests a potential upside of 5.36%, a figure that should pique the interest
of investors looking for growth opportunities in the healthcare sector.

In terms of valuation, CRL presents an intriguing opportunity. While the trailing
P/E ratio is currently unavailable, the forward P/E stands at a modest 15.24, indicating
that the stock may be reasonably priced relative to its expected earnings. Investors
should note the lack of data on the PEG ratio, Price/Book, Price/Sales, and EV/EBITDA,
which limits a comprehensive valuation analysis but underlines the importance of
considering forward earnings potential.

Performance metrics reveal a company in transition. Revenue growth is steady at 
0.60%, yet the EPS of -1.31 and a negative Return on Equity of -1.81% might raise
concerns about profitability. However, a robust free cash flow of $706.38 million
provides a buffer, offering CRL the financial flexibility to invest in growth and
innovation.

Charles River Laboratories does not offer a dividend, with a payout ratio of 0.00%,
signaling a focus on reinvestment into the business rather than returning capital
to shareholders at this time. This could appeal to investors who prioritize capital
appreciation over immediate income.

Analyst sentiment is cautiously optimistic. With 6 buy ratings and 12 hold ratings,
and notably no sell ratings, the consensus suggests confidence in CRL’s long-term
prospects. The absence of sell recommendations indicates that analysts believe the
company’s strategic initiatives and market position will drive future growth.

From a technical perspective, CRL is positioned just above its 200-day moving average
of $160.08 with a current price of $163.31, suggesting a neutral to slightly bullish
trend. The 50-day moving average of $159.12 supports this outlook. Additionally,
the Relative Strength Index (RSI) of 68.44 hints at the stock nearing overbought
territory, while the MACD of 0.99 compared to the signal line at 0.34 supports potential
upward momentum.

Charles River Laboratories operates through three primary segments: Research Models
and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.
Each segment plays a critical role in supporting the pharmaceutical and biotechnology
industries, offering services ranging from pre-clinical drug candidate screening
to quality control testing of biologics.

Founded in 1947, Charles River Laboratories has built a legacy of innovation and
reliability in the healthcare domain. Its strategic use of platforms like Logica
for advancing small molecule leads illustrates its commitment to leveraging cutting-
edge technology in drug development.

For investors, Charles River Laboratories represents a compelling blend of established
industry presence and forward-looking potential. With analysts signaling a 5.36%
upside, those willing to navigate the complexities of its financial metrics may 
find long-term value in CRL’s stock. As the healthcare landscape continues to evolve,
Charles River Laboratories’ role as a facilitator of drug discovery and development
positions it well for future growth.

Share on:
